Anna Flace

1.6k total citations · 1 hit paper
10 papers, 1.3k citations indexed

About

Anna Flace is a scholar working on Genetics, Hematology and Nutrition and Dietetics. According to data from OpenAlex, Anna Flace has authored 10 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Hematology and 3 papers in Nutrition and Dietetics. Recurrent topics in Anna Flace's work include Hemoglobinopathies and Related Disorders (5 papers), Iron Metabolism and Disorders (5 papers) and Immunotherapy and Immune Responses (3 papers). Anna Flace is often cited by papers focused on Hemoglobinopathies and Related Disorders (5 papers), Iron Metabolism and Disorders (5 papers) and Immunotherapy and Immune Responses (3 papers). Anna Flace collaborates with scholars based in Switzerland, United States and United Kingdom. Anna Flace's co-authors include Vania Manolova, Martin F. Bachmann, Philippe Saudan, Katrin Schwarz, Monika Bauer, Franz Dürrenberger, Reinhard Dummer, J Meyer, Burkhardt Seifert and Günter Burg and has published in prestigious journals such as Journal of Clinical Investigation, Blood and International Journal of Molecular Sciences.

In The Last Decade

Anna Flace

10 papers receiving 1.2k citations

Hit Papers

Nanoparticles target distinct dendritic cell populations ... 2008 2026 2014 2020 2008 250 500 750 1000

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Flace Switzerland 8 670 553 171 159 135 10 1.3k
Vania Manolova Switzerland 16 1.1k 1.7× 738 1.3× 214 1.3× 189 1.2× 213 1.6× 33 2.2k
José M. Rojas Spain 25 769 1.1× 486 0.9× 309 1.8× 260 1.6× 386 2.9× 58 2.0k
Anne Sundblad Sweden 20 1.1k 1.7× 713 1.3× 160 0.9× 185 1.2× 104 0.8× 31 1.9k
Douglas Hanlon United States 20 894 1.3× 598 1.1× 318 1.9× 177 1.1× 61 0.5× 38 1.6k
Claire Coeshott United States 15 522 0.8× 468 0.8× 222 1.3× 45 0.3× 81 0.6× 26 1.1k
Dodie Pouniotis Australia 21 764 1.1× 707 1.3× 198 1.2× 69 0.4× 61 0.5× 41 1.4k
S Badrinath India 18 779 1.2× 375 0.7× 422 2.5× 215 1.4× 72 0.5× 48 1.5k
Brandon J. DeKosky United States 14 946 1.4× 704 1.3× 222 1.3× 183 1.2× 505 3.7× 33 2.1k
Hakan Kalay Netherlands 31 1.5k 2.2× 1.3k 2.3× 258 1.5× 118 0.7× 144 1.1× 60 2.4k
Sofía Casares United States 25 1.3k 1.9× 504 0.9× 261 1.5× 43 0.3× 171 1.3× 70 2.1k

Countries citing papers authored by Anna Flace

Since Specialization
Citations

This map shows the geographic impact of Anna Flace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Flace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Flace more than expected).

Fields of papers citing papers by Anna Flace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Flace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Flace. The network helps show where Anna Flace may publish in the future.

Co-authorship network of co-authors of Anna Flace

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Flace. A scholar is included among the top collaborators of Anna Flace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Flace. Anna Flace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Flace, Anna, et al.. (2024). The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis. HemaSphere. 8(9). e147–e147. 2 indexed citations
2.
Flace, Anna, et al.. (2023). Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions. Haematologica. 108(10). 2703–2714. 5 indexed citations
3.
Zennadi, Rahima, Anna Flace, Giada Ingoglia, et al.. (2022). The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Blood. 140(7). 769–781. 19 indexed citations
4.
Flace, Anna, et al.. (2021). The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia. International Journal of Molecular Sciences. 22(2). 873–873. 19 indexed citations
5.
Manolova, Vania, et al.. (2019). Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia. Journal of Clinical Investigation. 130(1). 491–506. 68 indexed citations
6.
Gomes, Ariane C., Anna Flace, Philippe Saudan, et al.. (2017). Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines. Frontiers in Immunology. 8. 226–226. 37 indexed citations
7.
Manolova, Vania, et al.. (2017). Biomarkers Induced by the Immunomodulatory Bacterial Extract OM-85: Unique Roles for Peyer’s Patches and Intestinal Epithelial Cells. Journal of Clinical & Cellular Immunology. 8(2). 9 indexed citations
8.
Raaijmakers, Marieke I.G., et al.. (2015). A new live‐cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology. 24(5). 377–380. 26 indexed citations
9.
Manolova, Vania, Anna Flace, Monika Bauer, et al.. (2008). Nanoparticles target distinct dendritic cell populations according to their size. European Journal of Immunology. 38(5). 1404–1413. 1021 indexed citations breakdown →
10.
Meyer, J, et al.. (1997). Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.. PubMed. 57(22). 5073–6. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026